- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Sandra Cuellar, PharmD, BCOP, FASHP | Authors
Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast Cancer
September 21, 2021
In an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.
Sandra Cuellar, PharmD, BCOP, FASHP, on Cardiotoxicity With Margetuximab for HER2+ Metastatic Breast Cancer
August 27, 2021
An oncology pharmacist speaks about the occurance of left ventricular dysfunction noted with margetuximab in the treatment of HER2-positive metastatic breast cancer.
Sandra Cuellar, PharmD, BCOP, FASHP, on Infusion-Related Reactions With Margetuximab for HER2+ Metastatic Breast Cancer
August 26, 2021
An oncology pharmacist talks infusion-related reactions with margetuximab in the treatment of HER2-positive metastatic breast cancer.
Sandra Cuellar, PharmD, BCOP, FASHP, Discusses the Mechanism of Action of Margetuximab for HER2-Positive Metastatic Breast Cancer
August 23, 2021
Oncology pharmacist Sandra Cuellar, PharmD, BCOP, FASHP, details the unique mechanism of action of margetuximab in the treatment of HER2-positive metastatic breast cancer.